[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"early-pregnancy-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:early-pregnancy-loss":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,81,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100620469","early-preg-a-preconception-cohort-study-based-on-counterfactuals-to-study-maternal-embryonic-molecular-interactions-100620469",false,"NCT07358026","EARLY-PREG: A Preconception Cohort Study Based on Counterfactuals to Study Maternal-Embryonic Molecular Interactions","EARLY-PREG: A Preconception, Longitudinal, Bidirectional, and Counterfactual Cohort Study of Women Seeking Pregnancy, Designed to Investigate Maternal-Embryonic Molecular Interactions During the Peri-implantation Window","EARLY-PREG","Inclusion criteria:\n\n* being between 18 and 40 years of age\n* not being pregnant\n* normal colposcopy\n* body mass index (BMI) between 18 and 29\n* regular menstrual cycles (21-35 days)\n* absence of chronic diseases (hypertension, diabetes mellitus, cancer, depression, personality disorder, thyroid pathology, polycystic ovary syndrome, or hyperprolactinemia).\n* If seeking pregnancy, they were included if their partners were males between 18 and 40 years old, without pathologies (diabetes mellitus, depression, personality disorder, or cancer), were not taking chronic medication, without erectile disorders, BMI between 18 and 29.9, moderate alcohol use, and with no recreational drug use.\n\nExclusion criteria:\n\n* pregnant women\n* history of alcoholism\n* infertility treatment\n* endometriosis\n* pelvic inflammatory disease\n* pelvic surgery\n* allergy to latex or silicone\n* If seeking pregnancy, they were excluded if their partners were working in contact with pesticides, or with history of erectile dysfunction, or history of mumps in adulthood, or with chronic diseases, or with psychological problems.",true,"FEMALE","18 Years","40 Years",{"count":22,"type":23},223,"ESTIMATED","OBSERVATIONAL","EARLY-PREG is an open-cohort clinical study with a preconception, longitudinal, bidirectional and counterfactual design. The aim of this cohort is to investigate the proteomic signatures of maternal-embryonic communication by interrogating a growing biorepository of maternal fluids and tissues collected during the first two weeks after fertilisation.\n\nParticipants in the EARLY-PREG cohort consist of healthy couples seeking pregnancy, as well as women who are not seeking to conceive. The three main outcomes in the cohort are defined according to menstrual cycles in which conception is achieved and those in which conception is not achieved. Their clinical definitions are as follows:\n\n* Pregnancy with a full-term live birth refers to the cycle in which the ovum is fertilised, leading to pregnancy, with beta-hCG levels above the clinical threshold for a positive pregnancy test.\n* Early pregnancy loss refers to a miscarriage up to 12 6\u002F7 weeks.\n* Non-pregnancy refers to a menstrual cycle in which conception does not occur, confirmed by a clinically negative beta-hCG test. When referring to the same individual, this is, by definition, considered the counterfactual to the corresponding conception cycle.",[27,28,29,30,31],"Early Pregnancy","Early Pregnancy Loss","Childbirth","Healthy","Pregnancy",[33,34,35,36,37,38,39],"longitudinal study","counterfactual design","embryo-mother crosstalk","biorepository","maternal fluids","menstrual cycle","preconception open cohort","RECRUITING","2026-04-24",{"date":43,"type":44},"2026-04-29","ACTUAL",{"date":46,"type":44},"2017-07-11",{"date":48,"type":23},"2027-12",{"name":50,"class":51},"MELISA Institute Genomics & Proteomics Research SpA","INDUSTRY",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100631886","phase-3-optimal-time-interval-between-mifepristone-and-misoprostol-administration-for-early-pregnancy-loss-100631886","NCT07506512","Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss","TIME","Inclusion Criteria:\n\n* Able to participate in the informed consent process and provide a signed and dated consent form.\n* Stated willingness to comply with all study procedures.\n* Access to device with text or email capability.\n* Able to read and understand English.\n* Confirmed diagnosis of intrauterine embryonic\u002Ffetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40mm or an abnormal growth pattern diagnostic of early pregnancy loss.\n\nExclusion Criteria:\n\n* Incomplete or inevitable abortion.\n* Contraindication or allergy to mifepristone or misoprostol\n* Unable to return for clinic-based follow-up.",{"count":61,"type":23},1000,"INTERVENTIONAL",[64],"PHASE3","A prospective cohort study to explore the optimal time interval between mifepristone and misoprostol administration for medical management of early pregnancy loss. Participants will be followed to assess treatment success, satisfaction, and side effects.",[28],[68,69],"early pregnancy loss","miscarriage","NOT_YET_RECRUITING","2026-03-26",{"date":73,"type":44},"2026-04-01",{"date":75,"type":23},"2026-07",{"date":77,"type":23},"2031-12",{"name":79,"class":80},"University of Pennsylvania","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":52},"100482067","cohort-of-patients-presenting-unexplained-recurrent-miscarriages-and-identification-of-early-miscarriage-recidivism-factors-100482067","NCT05557201","Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors","FALCO","Inclusion Criteria:\n\n* Age 18 to 50 years\n* Patients who have had 3 (or more) early pregnancy losses occurring before 14 weeks of amenorrhea and\u002For at least 3 implantation failures.\n* Patients who have been informed and have not objected to participating in the study.\n* Patients covered by a social security system.\n\nExclusion Criteria:\n\n* patients who do not agree the use of their data\n* Patients on AME\n* Patients under legal protection","50 Years",{"count":90,"type":23},700,"About 1 to 3% of women of childbearing age suffer repeated early spontaneous miscarriages (RCF) defined by at least 3 fetal losses before 14 weeks of gestation. RCFs may be linked to parental chromosomal abnormalities, congenital or acquired uterine abnormalities, hormonal causes (e.g. type 1 and 2 diabetes, ovarian failure), infectious etiology, constitutional or acquired thrombophilia or sickle cell disease.\n\nThe presence of antiphospholipid antibodies, antithyroid and anti-transglutaminase antibodies in approximately 10% of cases suggests an autoimmune origin for these fetal losses. The role of other antibodies, in particular non-conventional antiphospholipid antibodies, remains to be established. Indeed half of RCF cases are thought to be due to an immunological dysregulation of the mother leading to a decrease in tolerance to the fetus. Several studies have shown immune abnormalities, such as an imbalance of pro and anti-inflammatory cytokines, an increase in cytotoxic cells and a defect in regulatory cells in the blood of patients. The assessment of these immune abnormalities is not currently performed routinely in France in women presenting with recurrent early miscarriages. When one of these known causes is excluded, it is unexplained RCF which represents 50% of RCF. Over half of these women with RCF may be linked to aneuploidies and primary spontaneous recurrent abortions. Assessing the degree of aneuploidy and the genetic origin of foetal losses remains difficult to date, as examination of the miscarriage product is rarely available, due to the spontaneous nature of the loss.\n\nAn implantation failure (IF) is defined as the absence of pregnancy following the transfer of a good-quality embryo into the uterine cavity. These implantation failures can be due to embryonic factors, maternal factors, or caused by inappropriate stimulation and\u002For difficult transfers. In the literature, recurrent implantation failure (RIF) is defined as the absence of pregnancy after 3 attempts of transferring good-quality embryos, taking maternal age into account Setting up a prospective cohort of patients with RFC is an essential step in exploring the aetiological factors of RCF and in order to enable better treatment.",[93,28],"Miscarriage",[93,95,96,97,98],"Prognostic factors","Biological collection","recurrent early pregnancy losses","repeated implantation failure","2025-12-12",{"date":101,"type":44},"2025-12-19",{"date":103,"type":44},"2022-10-24",{"date":105,"type":23},"2029-10",{"name":107,"class":80},"Assistance Publique - Hôpitaux de Paris",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":62,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":52},"100550872","phase-2-letrozole-and-misoprostol-for-early-pregnancy-loss-management-100550872","NCT06452719","Letrozole and Misoprostol for Early Pregnancy Loss Management","Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort Study","LeMi","Inclusion Criteria:\n\n* Able to participate in the informed consent process and provide a signed and dated consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Access to working mobile phone\n* English-speaking\n* Age 18 years or older\n* Confirmed diagnosis of intrauterine embryonic\u002Ffetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)\n\nExclusion Criteria:\n\n* Incomplete or inevitable abortion\n* Contraindication of allergy to letrozole or misoprostol\n* Unable to return for clinic-based follow-up\n* Twin or multiple pregnancy",{"count":117,"type":23},30,[119],"PHASE2","A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.",[28,122,93],"Miscarriage in First Trimester","2025-07-31",{"date":125,"type":44},"2025-08-05",{"date":127,"type":44},"2024-08-22",{"date":129,"type":23},"2026-07-15",{"name":79,"class":80}]